Author Correction: Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance

Jinfang Zhang^#¹, Xia Bu^#², Haizhen Wang^#³, Yasheng Zhu⁴, Yan Geng³, Naoe Taira Nihira¹, Yuyong Tan^{1

5}, Yanpeng Ci^{1

6}, Fei Wu^{1

7}, Xiangpeng Dai¹, Jianping Guo¹, Yu-Han Huang¹, Caoqi Fan^{3

8}, Shancheng Ren⁴, Yinghao Sun⁴, Gordon J Freeman^#⁹, Piotr Sicinski^#¹⁰, Wenyi Wei^#¹¹

Affiliations

¹ Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
³ Department of Cancer Biology, Dana-Farber Cancer Institute and Department of Genetics, Harvard Medical School, Boston, MA, USA.
⁴ Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
⁵ Department of Gastroenterology, the Second Xiangya Hospital of Central South University, Changsha, China.
⁶ School of Life Science and Technology, Harbin Institute of Technology, Harbin, China.
⁷ Department of Urology, Huashan Hospital, Fudan University, Shanghai, China.
⁸ Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, School of Life Sciences, Peking University, Beijing, China.
⁹ Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. gordon_freeman@dfci.harvard.edu.
¹⁰ Department of Cancer Biology, Dana-Farber Cancer Institute and Department of Genetics, Harvard Medical School, Boston, MA, USA. peter_sicinski@dfci.harvard.edu.
¹¹ Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. wwei2@bidmc.harvard.edu.

^# Contributed equally.

Published Erratum

Jinfang Zhang et al. Nature. 2019 Jul.

. 2019 Jul;571(7766):E10.

doi: 10.1038/s41586-019-1351-8.

¹ Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
³ Department of Cancer Biology, Dana-Farber Cancer Institute and Department of Genetics, Harvard Medical School, Boston, MA, USA.
⁴ Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
⁵ Department of Gastroenterology, the Second Xiangya Hospital of Central South University, Changsha, China.
⁶ School of Life Science and Technology, Harbin Institute of Technology, Harbin, China.
⁷ Department of Urology, Huashan Hospital, Fudan University, Shanghai, China.
⁸ Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, School of Life Sciences, Peking University, Beijing, China.
⁹ Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. gordon_freeman@dfci.harvard.edu.
¹⁰ Department of Cancer Biology, Dana-Farber Cancer Institute and Department of Genetics, Harvard Medical School, Boston, MA, USA. peter_sicinski@dfci.harvard.edu.
¹¹ Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. wwei2@bidmc.harvard.edu.

^# Contributed equally.

Abstract

An Amendment to this paper has been published and can be accessed via a link at the top of the paper. The original Letter has not been corrected.

Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance.
Zhang J, Bu X, Wang H, Zhu Y, Geng Y, Nihira NT, Tan Y, Ci Y, Wu F, Dai X, Guo J, Huang YH, Fan C, Ren S, Sun Y, Freeman GJ, Sicinski P, Wei W. Zhang J, et al. Nature. 2018 Jan 4;553(7686):91-95. doi: 10.1038/nature25015. Epub 2017 Nov 16. Nature. 2018. PMID: 29160310 Free PMC article.